← Leaderboards
Lanying Du
New York Blood Center
$16,789,459
Attributed
$20,683,700
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,683,700 · 12
By mechanism
R01$13,756,916 · 5
U19$3,774,241 · 1
R21$1,908,467 · 4
U01$1,082,076 · 1
R03$162,000 · 1
Top collaborators
- Fang Li5 shared
- Stanley Perlman5 shared
- Sara Lustigman2 shared
- Liang Qiao2 shared
Most similar at New York Blood Center
Same institution · by research overlap
- Sara Lustigman$21,771,096
- Shibo Jiang$8,062,102
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsVirusDesignBaseReceptor BindingNeutralizing AntibodyVaccinesAntibodiesViralFuturePandemic DiseaseIn VivoImmunogenicityEvaluationVirus DiseasesAnimal ModelMiddle East Respiratory Syndrome CoronavirusPathogenicitySars CoronavirusCoronavirus Spike ProteinVaccine CandidateImmune ResponseNonhuman PrimateStructure
Grant awards (32)
A Novel T cell-based Vaccine to Prevent Dengue/Zika virus infection$781,718
R01 · FY2025 · AI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$759,331
R01 · FY2025 · AI · contact PI
Rational design of a unique vaccine for emerging pandemic coronaviruses$755,225
R01 · FY2025 · AI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$759,331
R01 · FY2023 · AI · contact PI
Project 2: Nanobodies as Novel Entry Inhibitors of Pandemic Viruses$3,774,241
U19 · FY2022 · AI · contact PI
Structure-based design of coronavirus subunit vaccines$796,048
R01 · FY2022 · AI · contact PI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$759,731
R01 · FY2022 · AI · contact PI
Rational design and evaluation of novel mRNA vaccines against MERS-CoV$742,199
R01 · FY2022 · AI · contact PI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$766,055
R01 · FY2021 · AI · contact PI
Structure-based design of coronavirus subunit vaccines$728,965
R01 · FY2021 · AI · contact PI
Rational design and evaluation of novel mRNA vaccines against MERS-CoV$554,964
R01 · FY2021 · AI · contact PI
Rational design and evaluation of novel mRNA vaccines against MERS-CoV$339,869
R01 · FY2021 · AI · contact PI
Structure-based design of coronavirus subunit vaccines$102,509
R01 · FY2021 · AI · contact PI
Structure-based design of coronavirus subunit vaccines$839,218
R01 · FY2020 · AI · contact PI
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses$832,650
R01 · FY2020 · AI · contact PI
Rational design and evaluation of novel mRNA vaccines against MERS-CoV$816,658
R01 · FY2020 · AI · contact PI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$526,550
U01 · FY2020 · AI
A novel and effective nanobody to prevent and treat Zika virus infection$267,000
R21 · FY2020 · AI · contact PI
Structure-based design of coronavirus subunit vaccines$845,133
R01 · FY2019 · AI · contact PI
Rational design and evaluation of novel mRNA vaccines against MERS-CoV$821,329
R01 · FY2019 · AI · contact PI
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination$555,526
U01 · FY2019 · AI
A novel and effective nanobody to prevent and treat Zika virus infection$222,500
R21 · FY2019 · AI · contact PI
Structure-based design of coronavirus subunit vaccines$911,083
R01 · FY2018 · AI · contact PI
Rational design and evaluation of novel mRNA vaccines against MERS-CoV$844,900
R01 · FY2018 · AI · contact PI
A novel nanobody with good druggability to prevent and treat MERS-CoV infection$219,500
R21 · FY2018 · AI · contact PI
A novel nanobody with good druggability to prevent and treat MERS-CoV infection$263,400
R21 · FY2017 · AI · contact PI
Critical neutralizing domain-based vaccines against new SARS-like virus hCoV-EMC$253,650
R21 · FY2015 · AI · contact PI
B. subtilis spore-delivered M2e-FP-based mucosal universal influenza vaccines$213,750
R21 · FY2015 · AI · contact PI
B. subtilis spore-delivered M2e-FP-based mucosal universal influenza vaccines$256,500
R21 · FY2014 · AI · contact PI
Critical neutralizing domain-based vaccines against new SARS-like virus hCoV-EMC$212,167
R21 · FY2014 · AI · contact PI
Rational design of M2e-FP conserved epitope-based universal influenza A vaccines$81,000
R03 · FY2012 · AI · contact PI
Rational design of M2e-FP conserved epitope-based universal influenza A vaccines$81,000
R03 · FY2011 · AI · contact PI